» Articles » PMID: 16338246

Schizophrenia and Increased Risks of Cardiovascular Disease

Overview
Journal Am Heart J
Date 2005 Dec 13
PMID 16338246
Citations 343
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The aim of the study is to review the absolute and relative impacts of the major causes for premature mortality among patients with schizophrenia.

Data Sources: We reviewed published articles on causes of mortality in the general population as well as among patients with schizophrenia.

Study Selection: We selected articles which published total and cause-specific mortality rates.

Data Extraction: We reviewed the causes of mortality and their risk factors.

Data Synthesis: The average life expectancy of the general population is 76 years (72 years in men, 80 years in women), whereas the corresponding figure is 61 years (57 years in men, 65 years in women) among patients with schizophrenia. Thus, patients with schizophrenia have approximately a 20% reduced life expectancy compared with the general population. Although patients with schizophrenia are 10 to 20 times more likely than the general population to commit suicide, more than two thirds of patients with schizophrenia, compared with approximately one-half in the general population, die of coronary heart disease (CHD). The chief risk factors for this excess risk of death are cigarette smoking, obesity leading to dyslipidemia, insulin resistance and diabetes, and hypertension.

Conclusions: The chief cause of excess premature mortality among patients with schizophrenia is CHD, caused mainly by their adverse risk factor profile. Because patients with schizophrenia have less access to medical care, consume less medical care, and are less compliant with their regimens, the choice of antipsychotic drug regimens that do not further adversely affect their risk factor for CHD is a major clinical and public health challenge among patients with schizophrenia.

Citing Articles

Impact of non-participation bias due to psychiatric illness on mortality and cardiovascular event estimates: a Danish longitudinal population study.

Rygner Z, Ellervik C, Rasmussen M, Torp-Pedersen C, Poulsen H, Jorgensen A BMJ Public Health. 2025; 2(1):e000289.

PMID: 40018250 PMC: 11812749. DOI: 10.1136/bmjph-2023-000289.


Effects of aerobic training on brain architecture, hippocampal volume, cardiorespiratory parameters, and health-related quality of life among patients with schizophrenia: A systematic review.

Sharma A, Sharma N, Singh R, Chahal A Indian J Psychiatry. 2025; 66(11):997-1013.

PMID: 39790344 PMC: 11708968. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_735_23.


Evaluation of routine health monitoring for metabolic disorders in patients with serious mental illness on psychotropic medications: a study from Ethiopia.

Zeleke T, Teshome A, Assefa M, Chanie G, Abebe R BMC Psychiatry. 2024; 24(1):795.

PMID: 39533225 PMC: 11558983. DOI: 10.1186/s12888-024-06266-1.


Peripheral Lipid Signatures, Metabolic Dysfunction, and Pathophysiology in Schizophrenia Spectrum Disorders.

Wu S, Panganiban K, Lee J, Li D, Smith E, Maksyutynska K Metabolites. 2024; 14(9).

PMID: 39330482 PMC: 11434505. DOI: 10.3390/metabo14090475.


Biomarkers for Psychosis: Are We There Yet? Umbrella Review of 1478 Biomarkers.

Fuentes-Claramonte P, Estrade A, Solanes A, Ramella-Cravaro V, Garcia-Leon M, de Diego-Adelino J Schizophr Bull Open. 2024; 5(1):sgae018.

PMID: 39228676 PMC: 11369642. DOI: 10.1093/schizbullopen/sgae018.